In January 2014, the University of Colorado announced the launch of CariCord, the private family umbilical cord blood bank of their existing public cord blood bank. CariCord is the first company in the world to offer cord blood and tissue banking in an FDA licensed laboratory to private consumers and families. This public-private venture of ClinImmune Labs at the University of Colorado Anschutz Medical Campus in Metro Denver is positioned to change the face of cord blood banking in the U.S.

Cord blood is currently used in the treatment of over 80 diseases. As stem cell research and regenerative medicine continues to advance, this number is very likely to increase. Previously, cord blood processing and banking was limited to units that were donated for use by the general public. Now, CariCord allows families to preserve their child’s umbilical cord blood from birth to adulthood, in a secure state-of-the-art facility.

Brian Freed, a professor at the University Of Colorado School Of Medicine and Executive Director of ClinImmune Labs stated that cord blood units have been processed under federal contract since 2006, and ClinImmune was among the first to elevate their cord blood banking practices to FDA BLA licensure. He went on to state that with the formation of CariCord, they are among the first to leverage the research and technology of their lab to serve private consumers. CariCord models a sustainable pathway that responds to current private and federal demands for cord blood units.

“Our mission is to provide parents with the confidence that they have taken the best steps to protect their children's future,” said Calvin Cole, CariCord's newly appointed President and CEO. “By delivering the highest quality processing and storage of umbilical cord stem cell products available anywhere, we offer families peace of mind that they chose the only company offering banking under FDA licensed practices. CariCord's clients will have the confidence that they preserved their child's life-saving cells for the possibility of future care under the same rigorous standards of the University of Colorado bank that has a long-track record supplying successful transplant units worldwide.”
This news clearly illustrates the University of Colorado’s commitment to biotech innovation, development and commercialization. ClinImmune Labs currently operates the public University of Colorado Cord Blood Bank, and CariCord will benefit from the investments that they have previously made in the field of umbilical cord blood banking.

At a glance, CariCord is a partially public and partially private joint venture corporation (Delaware Corp.) with ClinImmune Labs, which is owned by the University of Colorado. CariCord’s laboratory processing will take place at the state-of-the-art FDA licensed ClinImmune Labs, on the campus of the University of Colorado Anschutz Medical Campus in Metro Denver, Colorado. CariCord’s corporate offices and customer service headquarters will be located in Irvine, California.

FaceBook  Twitter